Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma

被引:8
|
作者
Wu, Yu-Peng [1 ]
Lin, Yun-Zhi [1 ]
Lin, Min-Yi [1 ]
Lin, Ting-Ting [1 ]
Chen, Shao-Hao [1 ]
Wei, Yong [1 ]
Zheng, Qing-Shui [1 ]
Xue, Xue-Yi [1 ]
Xu, Ning [1 ]
机构
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Urol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China
来源
TUMORI JOURNAL | 2018年 / 104卷 / 06期
关键词
Bladder cancer recurrence survival; Nephroureterectomy; SEER; Segmental ureterectomy; Upper-tract urothelial carcinoma; UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; RADICAL NEPHROURETERECTOMY; INTRAVESICAL RECURRENCE; SEGMENTAL URETERECTOMY; SURGICAL-MANAGEMENT; OUTCOMES; EPIDEMIOLOGY; SURVEILLANCE; GUIDELINES;
D O I
10.5301/tj.5000705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC). Methods: We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS. Results: In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016). Conclusions: Use of Su should be more selective for high-grade tumors, as it correlates with shorter BCRS. Tumors located in the ureter are associated with shorter BCRS than those located in the renal pelvis.
引用
收藏
页码:451 / 458
页数:8
相关论文
共 50 条
  • [41] Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial
    van Doeveren, T.
    van Leeuwen, P. J.
    Aben, K. K. H.
    van der Aa, M.
    Barendrecht, M.
    Boeve, E. R.
    Cornel, E. B.
    van der Heijden, A. G.
    Hendricksen, K.
    Hirdes, W.
    Kooistra, A.
    Kroon, B. K.
    Leliveld, A. M.
    Meijer, R. P.
    van Melick, H.
    Merks, B.
    de Reijke, T. M.
    de Vries, P.
    Wymenga, L. F. A.
    Wijsman, B.
    Boormans, J. L.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2018, 9 : 121 - 129
  • [42] RISK STRATIFICATION FOR BLADDER RECURRENCE AFTER RADICAL NEPHROURETERECTOMY FOR UPPER URINARY TRACT UROTHELIAL CARCINOMA
    Ishioka, Junichiro
    Saito, Kazutaka
    Matsuoka, Yoh
    Numao, Noboru
    Koga, Fumitaka
    Masuda, Hitoshi
    Fujii, Yasuhisa
    Sakai, Yasuyuki
    Okuno, Tetsuo
    Arisawa, Chizuru
    Kamata, Shigeyoshi
    Nagahama, Katsushi
    Yonese, Junji
    Noro, Akira
    Tsujii, Toshihiko
    Morimoto, Shinji
    Kitahara, Satoshi
    Goto, Shuichi
    Higashi, Yotsuo
    Kihara, Kazunori
    JOURNAL OF UROLOGY, 2013, 189 (04): : E162 - E162
  • [43] Endoscopic manipulation of upper tract urothelial carcinoma results in a higher risk of subsequent bladder recurrence
    Perlmutter, M.
    Shah, O.
    Godoy, G.
    Stifelman, M.
    Taneja, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 77 - 77
  • [44] CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma
    Chung, Shiu-Dong
    Huang, Kuo-How
    Lai, Ming-Kuen
    Huang, Chao-Yuan
    Chen, Chung-Hsin
    Pu, Yeong-Shiau
    Yu, Hong-Jeng
    Chueh, Shih-Chieh
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (05) : 743 - 753
  • [45] Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy
    Ishioka, Junichiro
    Saito, Kazutaka
    Kijima, Toshiki
    Nakanishi, Yasukazu
    Yoshida, Soichiro
    Yokoyama, Minato
    Matsuoka, Yoh
    Numao, Noboru
    Koga, Fumitaka
    Masuda, Hitoshi
    Fujii, Yasuhisa
    Sakai, Yasuyuki
    Arisawa, Chizuru
    Okuno, Tetsuo
    Nagahama, Katsuhi
    Kamata, Shigeyoshi
    Sakura, Mizuaki
    Yonese, Junji
    Morimoto, Shinji
    Noro, Akira
    Tsujii, Toshihiko
    Kitahara, Satoshi
    Gotoh, Shuichi
    Higashi, Yotsuo
    Kihara, Kazunori
    BJU INTERNATIONAL, 2015, 115 (05) : 705 - 712
  • [46] Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma
    Xiaoying Li
    Ming Cui
    Xiaobin Gu
    Dong Fang
    Hongzhen Li
    Shangbin Qin
    Kunlin Yang
    Tianzhao Zhu
    Xuesong Li
    Liqun Zhou
    Xian-Shu Gao
    Dian Wang
    World Journal of Surgical Oncology, 18
  • [47] Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma
    Li, Xiaoying
    Cui, Ming
    Gu, Xiaobin
    Fang, Dong
    Li, Hongzhen
    Qin, Shangbin
    Yang, Kunlin
    Zhu, Tianzhao
    Li, Xuesong
    Zhou, Liqun
    Gao, Xian-Shu
    Wang, Dian
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [48] RACIAL/ETHNIC DIFFERENCES IN UPPER-TRACT UROTHELIAL CANCER
    Hosain, G. M. Monawar
    Khan, Myrna
    Amiel, Gilad
    Lerner, Seth
    Latini, David
    Chen, John
    JOURNAL OF UROLOGY, 2011, 185 (04): : E267 - E267
  • [49] The Limited Value of Upper-Tract Urine Cytology for the Diagnosis of Upper Tract Urothelial Carcinoma
    Hayakawa, N.
    Kikuchi, E.
    Matsumoto, K.
    Kouno, H.
    Mizuno, R.
    Nagata, H.
    Asanuma, H.
    Miyajima, A.
    Nakagawa, K.
    Oya, M.
    UROLOGY, 2012, 80 (03) : S23 - S23
  • [50] Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity
    Masson-Lecomte, Alexandra
    EUROPEAN UROLOGY, 2025, 87 (04) : 453 - 454